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The loss of P2X7 receptor 
expression leads to increase 
intestinal glucose transit and 
hepatic steatosis
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In intestinal epithelial cells (IEC), it was reported that the activation of the P2X7 receptor leads to the 
internalization of the glucose transporter GLUT2, which is accompanied by a reduction of IEC capacity 
to transport glucose. In this study, we used P2rx7−/− mice to decipher P2X7 functions in intestinal 
glucose transport and to evaluate the impacts on metabolism. Immunohistochemistry analyses 
revealed the presence of GLUT2 at the apical domain of P2rx7−/− jejunum enterocytes. Positron 
emission tomography and biodistribution studies demonstrated that glucose was more efficiently 
delivered to the circulation of knockout animals. These findings correlated with increase blood glucose, 
insulin, triglycerides and cholesterol levels. In fact, P2rx7−/− mice had increased serum triglyceride and 
cholesterol levels and displayed glucose intolerance and resistance to insulin. Finally, P2rx7−/− mice 
developed a hepatic steatosis characterized by a reduction of Acaca, Acacb, Fasn and Acox1 mRNA 
expression, as well as for ACC and FAS protein expression. Our study suggests that P2X7 could play a 
central role in metabolic diseases.
Adenosine 5′-triphosphate (ATP) is secreted in the extracellular environment where it acts as a signaling molecule1. 
Extracellular ATP activates a number of receptors amongst which the ionotropic P2X7 receptor that belongs to the 
P2X receptor family of gated-ion channel2. P2X7 expression is ubiquitous, although, it was often associated with 
hematopoietic cells where its activity is key for the maturation of IL-1β amongst other functions3. In the intes-
tine, P2X7 expression was found in intestinal epithelial cells (IEC)4–7, as well as in neurons of the enteric nervous 
system where it regulated intestinal motility8 and post-infection visceral pain9. Its expression in the intestinal 
lamina propria of patients suffering from Crohn’s disease was associated with increased inflammation10. In Peyer’s 
patches of the mouse ileum, P2X7 stimulated apoptosis of T helper cells in order to maintain appropriate immune 
responses toward invading bacteria11. Aside from its obvious role in immunology, P2X7 was identified as an 
important regulatory element of metabolism12. In fact, P2rx7 knockout mice under diverse genetic background 
suffer from hyperglycemia, glucose intolerance, and impaired beta cells function in response to a high-sucrose 
diet13, as well as abnormal fat distribution14. It was also reported that absence of P2X7 expression protected P2rx7 
knockout mice from streptozotocin-induced diabetes15. The protective effect could be recapitulated by intraperi-
toneal injections of P2X7 antagonist Brilliant Blue G. It was proposed that P2X7 participated to the development 
of type 1 diabetes by contributing to the recruitment of antigen presenting cells and lymphocytes to the pan-
creas and pancreatic lymph node15. More recently, P2X7 was identified as an attractive pharmacological target 
to treat early phase diabetic retinopathy, a common consequence of long-term diabetes16. Aside from exacer-
bated immune responses as reported in both of these studies, diabetes and diabetic retinopathy share a common 
denominator that is high blood glucose levels and/or poor glycemic regulatory mechanism in which the P2X7 
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is involved as depicted above. In this context, it was reported that P2X7 expression was upregulated in IEC in 
response to high glucose concentration17. These findings are further supporting the idea that P2X7 expression 
could be an important receptor in maintaining metabolism homeostasis.
In IEC, the sodium/glucose cotransporter SGLT-1 ensures glucose entries and the subsequent export toward 
the bloodstream is mediated by the glucose transporter type 2 GLUT218. However, other studies suggested that 
apical GLUT2 might be required to accommodate the important concentration of luminal glucose in postprandial 
conditions19–21. Despite this debate about the presence and function of GLUT2 at the IEC apical compartment, 
GLUT2 is required for glucose export to the blood stream, and as such represent an interesting target to control 
glycaemia. In this context, we previously showed that the stimulation of the P2X7 receptor initiated the internal-
ization of GLUT2 in IEC. This delocalization of GLUT2 was accompanied by a significant reduction of glucose 
transport by IEC4.
In this work, we have used live positron emission tomography (PET) imaging and biodistribution analyses to 
monitor the enteral absorption and transport of a [18F]-FDG/glucose solution in P2rx7+/+ and P2rx7−/− mice. 
Supporting our previous in vitro studies4, we found that in P2rx7−/− mice the intestine more efficiently transport 
glucose thus leading to a rapid increase in blood glucose concentrations. Hence, we determined that knockout 
animals were suffering from symptoms mimicking human metabolic diseases, including hepatic steatosis.
Results
GLUT2 jejunum localization in IEC. GLUT2 is constitutively expressed at the basolateral membrane of 
enterocytes whereas its apical expression is regulated, although the presence of GLUT2 in this compartment is 
still a matter of debate18,22,23. In vitro, we determined that P2X7 stimulation induced GLUT2 internalization4. To 
circumvent the potential influence of luminal glucose and insulin on GLUT2 localization24, we starved P2rx7−/− 
mice and wild-type littermates for 6 h prior to experiments. Under these conditions, immunohistochemistry 
studies showed that GLUT2 was mainly located at the apex of jejunum villosities (Fig. 1A–D). We clearly see the 
localization of GLUT2 at the enterocyte basolateral membranes (Fig. 1A–F, black arrowheads). GLUT2 stain-
ing is barely visible at the apical membrane of P2rx7+/+ enterocytes (Fig. 1E, black arrows). In P2rx7−/− mice 
(Fig. 1F), strong GLUT2 staining was found at the apical compartments (black arrows) and basolateral mem-
branes (black arrowheads) of enterocytes. The apparent modulation of GLUT2 localization at the apical mem-
brane of P2rx7−/− enterocytes cannot be attributable to an increase protein expression since the overall GLUT2 
expression in isolated IEC remains the same (Fig. 1G). The presence of apical GLUT2 was accompanied by a 
significant augmentation in the concentration of blood glucose measured in 12-week-old knockout mice as com-
pared to wild-type littermates (Fig. 1H). The higher glycaemia values were maintained through time. The exper-
iments were stopped at 52 weeks of age, as some mice had serious health issues that included loss of sight, severe 
obesity and mobility difficulties. In light of these results, we hypothesis that the relocalization of GLUT2 at the 
apical compartment of P2rx7−/− enterocytes could lead to a more efficient capacity of P2rx7−/− mice to absorb 
and transport luminal glucose.
In vivo glucose absorption and biodistribution. To study the potential differential efficiency to absorb, 
transport and distribute glucose, P2rx7+/+ and P2rx7−/− mice were gavage with a solution of glucose supple-
mented with [18F]-FDG. The progression of the [18F]-FDG tracer through the digestive tract and distribution to 
other organs was monitored by live PET scans as showed in the movie (video 1.mp4, supplemental data). As we 
observed in this video, the distribution and progression of the [18F]-FDG tracer appears to progress more rapidly 
through the gastro-intestinal tract of P2rx7−/− mouse when compared to the P2rx7+/+ animal. Hence, we noticed 
that the proximal region of the small intestine of the P2rx7−/− mouse is practically devoid of [18F]-FDG signals at 
the end of the animation, being mostly concentrated in the most distal section of the intestine, when compared 
to the P2rx7+/+ animal. These observations are better illustrated in Fig. 2, where time-frame captions are showed 
for P2rx7+/+ (Fig. 2A) and P2rx7−/− (Fig. 2B) mice. As observed in the animations, the [18F]-FDG signal was ini-
tially more intense in the intestine of the P2rx7−/− mouse (Fig. 2B) from 5 to 30 min following the gavage when 
compared to the P2rx7+/+ animal (Fig. 2A). At 60 and 90 min, we clearly saw a reduction of the signal intensity 
in the proximal and mid-intestine and a significant accumulation in the distal intestine of the P2rx7−/− mouse 
when compared to the lower signal intensity and spread distribution of the tracer in the P2rx7+/+ animal. For the 
P2rx7+/+ mouse, we could also see [18F]-FDG activity appearing in the heart at 60 and 90 min; a signal absent 
in the P2rx7−/− animal. This was further illustrated in Fig. 2C, which showed a significantly reduced uptake of 
[18F]-FDG in the heart of P2rx7−/− mouse. This surprising result may be related to the metabolic status of the 
P2rx7−/− mice as we discussed below. To further support the live imaging, the progression and signal intensity of 
the [18F]-FDG tracer was calculated at different time points in the different organs of interest (Fig. 3).
The transition rate of the [18F]-FDG/glucose solution through the stomach is similar between the two groups 
of mice as illustrated by the two parallel curves of %ID/g of tissue over time (Fig. 3A, upper panel). However, the 
decreased AUC values (Fig. 3A, lower panel) showed that the retention of glucose in the stomach of P2rx7−/− 
mouse was significantly less when compared to P2rx7+/+ animals. As a consequence, there is a greater amount 
of the [18F]-FDG/glucose solution reaching the intestine of P2rx7−/− mice. This is confirmed by the distribution 
curves of Fig. 3B, which suggest an increase overall availability of the [18F]-FDG/glucose solution in the intestine 
of P2rx7−/− mouse. This increase activity in P2rx7−/− animals seems inconsistent with the significant and robust 
reduction in the [18F]-FDG quantity found at 90 min in the proximal small intestine of P2rx7−/− mice as com-
pared to wild-type animals (Fig. 3G). However, PET images suggest a faster transit of the [18F]-FDG through the 
proximal small intestine of the P2rx7−/− mice, which would be consistent with a lower intestinal uptake of the 
radiotracer. In addition, it is technically impossible by PET imaging to make a distinction between the [18F]-FDG 
activity found in the intestine lumen vs. the activity localized in the intestinal layers. This limitation explains 
our inability to measure uptake differences for each of the time points presented in Fig. 3B. Finally, the apparent 
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Figure 1. The absence of P2X7 expression modulates GLUT2 localization at the apical compartment of mouse 
jejunum enterocytes and increases glycaemia. (A–F) Immunohistochemical localization of GLUT2 in the 
jejunum enterocytes of P2rx7+/+ (A,C,E) and P2rx7−/− mice (B,D,F). In mouse jejunum, GLUT2 was found 
mainly located at the apex of villi in both P2rx7+/+ and P2rx7−/− mice. We observed a differential localization of 
GLUT2 with increase apical (black arrows) and basolateral (black arrowheads) signals for GLUT2 in P2rx7−/− 
mice (B,D) as compared to P2rx7+/+ animals (A,C). Panels E and F are a 2.5x magnification of the selected 
area (black box) showed in panels C and D, respectively. The micrographs are representative of four P2rx7+/+ 
mice and four knockout animals with two different animals shown on panels A–D. For panels A to D the scale 
bars = 50 μm at an original magnification of 40x. (G) Western blot analysis of isolated mouse jejunum IEC 
showing the absence of P2X7 expression in knockout animals and the similar expression of GLUT2 in both 
animal groups. Whole lung protein lysate was used as a positive control for P2X7 expression and VINCULIN 
as a control for protein loading and integrity. H) Blood glucose levels were determined after 6 h of diurnal 
fasting and reported as the mean ± SEM. P2rx7+/+ (open bars) and P2rx7−/− (black bars) male mice of different 
age (n = 5 to 9 animals per groups) were used and the statistical significance determined by an unpaired t test, 
where *p < 0.05.
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Figure 2. Maximum intensity projection 3D rendering at different time points following per os inoculation 
of FDG in the stomach of (A) P2rx7+/+ and (B) P2rx7−/− mice, showing the progression of FDG through the 
digestive tract. (C) Representative transaxial (top panel) and coronal (bottom panel) 5-mm thick slices through 
the heart at 90 minutes post-inoculation showing normal myocardial FDG uptake in a P2rx7+/+ mouse (left) 
and significantly reduced uptake in a P2rx7−/− mouse (right). Note the 3-fold enhanced image contrast in the 
P2rx7−/− panel to allow visualization of the low FDG uptake in the heart. The presence of FDG activity in 
the esophagus results from accidental contamination during the radiotracer administration. White arrows: 
stomach; Red arrows: heart; Blue arrows: bladder; Gray arrows: esophagus.
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Figure 3. Glucose/[18F]-FDG solution is absorbed and distributed at different rates by organs in P2rx7−/− 
mice. (A–F) A dose of 50 mg D-glucose supplemented by [18F]-FDG was given per os to 6 h-fasted mice and 
absorption followed live using PET imaging. The upper panels are showing the absorption through time in 
units of percent injected dose per g of tissue (%ID/g) for the selected organs, whereas the lower panels present 
the area under the curve (AUC) showing the amount of radiotracer found in the selected organs after 90 
min. Results are expressed as the mean ± SEM of the %ID/g for 3 P2rx7+/+ and 3 P2rx7−/− mice. Statistical 
significance was determined by an unpaired t test, where *p < 0.05. (G) Following the 90 min PET acquisition, 
the selected organs were harvested and the [18F]-FDG uptake measured in a Packard Cobra II E5003 gamma 
counter. Results are expressed as the mean ± SEM of the %ID/g for 3 P2rx7+/+ and 3 P2rx7−/− mice. Statistical 
significance was determined by an unpaired t test, where *p < 0.05.
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6SCIeNtIFIC RePoRts | 7: 12917  | DOI:10.1038/s41598-017-13300-8
discrepancies between the observations showed in the video and Fig. 2 and those presented in Fig. 3B could also 
be attributable to the fact the presented curves are the results of measurements of the [18F]-FDG activity col-
lected from the whole small intestine and not from a particular region such as the jejunum. Next, we determine 
the distribution of [18F]-FDG over time in the heart (Fig. 3C) and the vascularized shoulder muscle (Fig. 3D) 
of mice. For the heart, the accumulation of the [18F]-FDG tracer followed a linear steady-state kinetic in both 
P2rx7+/+ and P2rx7−/− mice (Fig. 3C, upper panel) as previously reported25. Overall, there is a significant reduc-
tion of [18F]-FDG signals in the organ of knockout mice, which correlates with a marked reduction of AUC values 
(Fig. 3C, lower panel) in these animals. The marked reduction in the %ID/g of tissue in the heart of P2rx7−/− mice 
could be partially explained by the fact that about 70% of the ATP produced in the heart comes principally from 
fatty acid (FA) oxidation and not from glucose26. Hence, the use of FA as the heart energy source is exacerbated 
in different diabetes rodent models26. Since the determination of [18F]-FDG uptake by the heart does not seem 
to adequately reflect the level of circulating glucose, we measured, on the opposite, a significant accumulation of 
[18F]-FDG over time in the vascularized shoulder muscle (Fig. 3D). These latest findings suggest that glucose was 
more efficiently transported in the circulation of P2rx7−/− than in P2rx7+\+ mice (Fig. 3D). No significant differ-
ence was observed between animal groups for the kidneys (Fig. 3E) and bladder (Fig. 3F).
Following the PET procedures, organs of interest were harvested and [18F]-FDG biodistribution measured 
using a Packard Cobra II E5003 gamma radiation counter. As for the PET studies, a significant reduction in the 
level of [18F]-FDG was measured in the stomach and heart of P2rx7−/− mice as compared to wild-type animals 
(Fig. 3G). As stated above, contrary to the PET measurement for which the intestine was measured as a whole, the 
biodistribution of [18F]-FDG was markedly and significantly reduced in the proximal region of the small intestine 
(duodenum and proximal jejunum) of P2rx7−/− mice as compared to P2rx7+/+ animals (Fig. 3G). It is worth 
mentioning that the proximal small intestine is the region where most of the glucose is absorbed under normal 
conditions23. No significant difference was observed for the distal small intestine (distal jejunum and ileum). The 
reduction in the level of [18F]-FDG in the proximal small intestine of knockout animals and increase in blood, 
suggest that glucose is rapidly absorbed by enterocytes and transported to the blood stream, thus supporting the 
idea that the P2X7 receptor is involved in the regulation of glucose entries as we previously showed in vitro4. A 
slight, but significant increase in [18F]-FDG concentration was also measured in the pancreas of P2rx7−/− for 
which the [18F]-FDG levels increase from 0.69 ± 0.14 %ID/g of tissue for wild-type mice to 1.27 ± 0.10 %ID/g in 
P2rx7−/− animals (Fig. 3G).
P2rx7 deficient mice display higher glycaemia, increase weight gain and dyslipidemia. In light 
of the [18F]-FDG PET and biodistribution assays as well as increase glycaemia in KO animals, it was not surprising 
to find a significant increase in the weight of P2rx7−/− mice as soon as 6 weeks of age when compared to wild-type 
animals (Fig. 4A). The weight increase was maintained through time as shown by the higher AUC value (Fig. 4B). 
Although this not the first report showing that P2rx7 deficient mice have aberrant glycaemia and increase weight 
gain13,14, this study is the first to suggest that the increased glycaemia and weight gain might come from more efficient 
glucose uptake by the intestine. Furthermore, the weight increase measured in P2X7−/− animals was not the con-
sequence of increase food uptake (supplemental Fig. S1A), a reduction of activity (supplemental Fig. S1B), nor 
a modulation of energy expenditure (supplemental Fig. S1C). The increase in plasma glucose concentration was 
validated in 12-week-old mice using an automated clinical analyzer (Fig. 4C), as previously described27. Increases 
in serum triglyceride (TG) (Fig. 4D) and cholesterol (Fig. 4E) levels were also measured in P2rx7−/− mice when 
compared to P2rx7+/+ animals. The increase in blood glucose, TG and cholesterol concentrations was accompa-
nied by a significant increase in serum insulin level in P2rx7−/− mice (Fig. 4F). The presence of high blood glucose 
concentration despite a significant increase in serum insulin level leads us to suspect that P2rx7−/− mouse might 
be insulin resistant. The HOMA2-IR test was used to determine the relative resistance of P2rx7−/− mice to insulin 
and pancreatic β-cell function (HOMA2-%B). As shown on Fig. 4G, P2rx7−/− animals had higher HOMA2-IR 
values, thus supporting the idea that knockout mice could be insulin resistant. However, the apparent insulin 
resistance does not appear to be a consequence of β-cells malfunction as HOMA2-%B values were not signifi-
cantly different between the two animal groups (Fig. 4H).
The absence of P2X7 expression increases the susceptibility of mice to glucose intolerance 
and insulin resistance. In light of the HOMA2-IR test results, we further our investigation to determine if 
P2rx7−/− mice had impaired glucose tolerance and/or were insulin resistant. Oral glucose tolerance test (OGTT) 
results revealed that P2rx7−/− mice reached a significantly higher glycaemia 15 min following gavage (Fig. 5A). 
This difference in glycaemia was maintained up to 90 min post-gavage. The calculated AUC value, which is an 
indication of the blood glucose load, was significantly increased for the P2rx7−/− mice (Fig. 5B), suggesting that 
these mice could have a defect in their ability to manage glycaemia. To determine the ability of P2rx7−/− mice to 
clear glucose and manage insulin, animals were subjected to intraperitoneal glucose (IPGTT) and insulin (IPITT) 
challenges. The glycaemia was significantly higher in P2rx7−/− mice when compared to control littermates in both 
IPGTT (Fig. 5C,D) and IPITT (Fig. 5E,F) assays. Since the HOMA2-%B values were similar between the two 
groups, it seems that P2X7−/− mouse intolerance to glucose could be linked to insulin resistance.
P2rx7−/− mice display hepatic steatosis. Histologic analyses of H&E-stained liver sections of 
12-week-old mice (Fig. 6A,B) revealed the presence of vacuoles, microvacuoles in particular, in the liver of 
P2rx7−/− animals (Fig. 6B) as compared to control mice (Fig. 6A). Oil red O staining of liver sections showed 
that lipid droplets accumulate in hepatocyte cytoplasmic vacuoles in P2rx7−/− mice as soon as 21 days postnatal 
(Fig. 6C–E; supplemental Fig. S2). The accumulation of hepatic lipid increases with times as shown by the mark 
staining in 3 months old (Fig. 6F–H) and 52-month-old (Fig. 6I–K) P2rx7 knockout animals. The lipid deposi-
tion was mainly associated with macrovacuoles formation, with sparse microvacuoles also present. Although the 
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Figure 4. P2rx7−/− mice have increased body weight and abnormal glucose, insulin, triglyceride and 
cholesterol levels which could be associated to apparent resistance to insulin. (A) The weight of six P2rx7+/+ and 
eight P2rx7−/− male mice was measured every week between 9–10 h AM starting at weaning (3-week-old mice) 
to 20-week-old mice. The results are expressed as the mean ± SEM and statistical significance was determined 
by an unpaired t test, where *p < 0.05. (B) The Area Under the Curve (AUC) of the weight of experimental 
animals was determined by the trapezoidal method and expressed as the mean ± SEM. The statistical 
significance was determined by an unpaired t test, where **p < 0.01. Serum biochemical analyses were realized 
on 12-week-old male mice (9 P2rx7+/+ and 9 P2rx7−/−) following 6h of diurnal fasting. Glucose (C), triglyceride 
(TG) (D) and total cholesterol (E) concentrations were determined using an automated clinical analyzer as 
described in the materials and methods section, whereas serum insulin concentration (F) was measured by 
an ELISA test. Results are presented as the mean ± SEM, where *p < 0.05 as determined by unpaired t tests. 
The HOMA2-IR (G) and HOMA2-%B (H) indices were calculated from the glucose and insulin levels found 
in panels C and F using the HOMA calculator presented in the M&M section. Results are expressed as the 
mean ± SEM. Statistical significance was determined by an unpaired t test, where *p < 0.05.
www.nature.com/scientificreports/
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vacuole distribution was mostly centrilobular, some lipid vacuoles were also observed in the midzonal region. 
Reddish-colored pixels were quantified as described in the materials and methods section and are presented in 
histograms (Fig. 6E,H,K). These results are confirming the accumulation of lipids in hepatocytes and the develop-
ment of hepatic steatosis in P2rx7 knockout mice when compared to age-matched control animals.
Genes associated with liver lipid metabolism are downregulated in P2rx7−/− mice. 
Accumulation of lipids in hepatocytes might arise from increased lipid synthesis, or decreased lipid oxidation 
amongst other factors28. In this context, we analyzed the mRNA expression of acetyl-CoA carboxylase alpha 
and beta (Acaca, Acacb), fatty acid synthases (Fasn) that are involved in de novo synthesis of fatty acids, and 
acyl-CoA oxidase 1 (Acox1), which is key for lipid peroxisomal β-oxidation29. Despite the increased lipid accu-
mulation in the liver of P2rx7−/− mice, we measured a significant reduction in Acaca, Acacb, Fasn and Acox1 
expression (Fig. 7A). The reduced gene expression of Acaca, Acacb and FasN was accompanied by a reduc-
tion of protein expression as well (Fig. 7B and C). Indeed, using a pan-ACC antibody we observed and quan-
tified a significant reduction in the expression of ACC in the liver of P2rx7−/− mice as compared to control 
animals (Fig. 7B). Similarly, FAS protein expression was significantly reduced in the liver of knockout mice 
(Fig. 7C). On the opposite, no difference was observed for the expression of the Mlxipl gene that encodes for 
the carbohydrate-responsive element-binding protein (ChREBP) (Fig. 7A). AMPK, PPARα and PPARβ are 
Figure 5. Glyceamia in P2rx7−/− mouse following glucose and insulin challenge. Blood glucose concentration 
during (A) OGTT, (B) IPGTT and (C) IPITT over time following the gavage of 50 mg of D-glucose or the 
intraperitoneal injection of 2 g D-glucose/kg or 0.5 U/kg of insulin following 6h of fasting. Results are presented 
as the mean ± SEM of 8 to 10 animals per group, where *p < 0.05 as determined by multiple t tests. (B,D,F) For 
each experimental condition, AUC was calculated using the trapezoidal method. Results are presented as the 
mean ± SEM of 8 to 10 animals per group, where *p < 0.05 as determine unpaired t tests.
www.nature.com/scientificreports/
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well-described metabolic regulators and modulators of the above-described genes30–33. However, western blot 
analysis of AMPK, PPARα and PPARβ liver expression as well as AMPK phosphorylation of Thr172 did not 
revealed any significant difference between the two animal groups (Fig. 7D).
Discussion
The ATP-gated P2X7 receptor regulates multiple physiological functions under normal and pathological condi-
tions. Amongst the recent functions associated with this particular receptor, the regulation of energy metabolism 
has emerged13,14,34,35. Here, we showed that the loss of P2X7 receptor expression lead to the increase expression 
of GLUT2 at the apical compartment of P2rx7−/− mouse enterocytes under basal fasting condition. These results 
confirmed our previous finding that showed the internalization of GLUT2 following the stimulation of the P2X7 
receptor in intestinal epithelial cell lines4. In fact, the apical localization of GLUT2 in P2xr7−/− mouse was similar 
to its expression in enterocytes of insulin resistant mouse24. The apical expression of GLUT2 was also observed in 
enterocytes of ob/ob and high fat-fed mice and in patients suffering from morbid obesity36. It was suggested that 
the apical localization of GLUT2 might favor glucose entries in the bloodstream and could thus contribute to the 
increase of glycaemia36. We could not find a significant overall difference in the efficiency of glucose absorption 
in the intestine using live PET imaging, which we believed was mainly due technical limitations as described 
above. However, the biodistribution analysis clearly showed a mark reduction of [18F]-FDG/glucose levels in the 
proximal intestinal region suggesting a rapid efficient absorption and transport of the glucose solution by the 
intestine of P2rx7−/− mice as compared to P2rx7+/+ littermates. Few studies have used PET imaging to study live 
enteral glucose absorption. One of these studies has determined the distribution pattern of radiolabeled glucose 
Figure 6. Oil red O staining reveals that P2rx7−/− mice accumulate lipids in their hepatocytes over time. 
Liver sections of 12-week-old (A) P2rx7+/+ and (B) P2rx7−/− mice were H&E stained and lipid-enriched 
microvacuoles could be observed in the liver of knockout animals (inserts). Magnification of 40x where scale 
bars = 100 μm, and inserts are a zoom of the select zone showed by the white box. Oil red O staining for 21-day-
old (C–E), 12-week-old (F–H) and 52-week-old (I–K) mice showed increase staining in P2rx7−/− animals (D, 
G, J) as compared to control littermates (C,F,I) over time. Magnification of 20x, where scale bars = 100 μm. 
Red-colored pixels were quantified as described in the M&M section and results presented as the mean ± SEM 
of three independent fields per mice for (E) four 21-day-old P2rx7+/+ and 4 P2rx7−/− mice, (H) eight 12-week-
old mice per group and (K) 7 P2rx7+/+and 13 P2rx7−/− 52-week-old mice. Statistical significance was 
determined by comparing the pixel averages using an unpaired t test, where *p < 0.05 and **p < 0.01.
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Figure 7. The expression of Acaca, Fasn and Acox1 is downregulated in the liver of P2rx7−/− mice. (A) Livers 
of control wild-type littermates (open circles) and of P2rx7−/− mice (close circles) were harvested and mRNA 
extracted prior to quantitative real-time PCR assay. The relative mRNA expression was expressed as the ratio of 
the expression over TATA-box binding protein gene expression (Tbp). Results are presented as the mean ± SEM, 
where *p < 0.05 as determine by multiple t tests. Liver lysates were also obtained and (B) ACC and (C) FAS 
protein expression determined by Western blots. β-Tubulin expression was used as a control of protein integrity 
and to ensure equal loading. Signal intensity was quantified by densitometry and reported as the mean ± SEM of 
the ratio of protein expression over β-tubulin, where *p < 0.05 as determine by an unpaired t tests. (D) Hepatic 
levels of AMPK phosphorylation of Thr172 and protein expression for AMPK, PPARα, and PPARβ determined 
by Western blots. GAPDH expression was used as a control of protein integrity and to ensure equal loading.
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derivative 60 min following gavage37. The reported distribution was similar to the pattern we measured in this 
work for P2rx7+/+ animals. At this time, it was concluded that SGLT1 was the main cellular entity responsible 
for the absorption of glucose by enterocytes37. We cannot argue against the importance of SGLT1 in this process, 
however, our work also points out at an important contribution of GLUT2 in this process. We have shown that 
GLUT2 expression was increased at the apical compartment of P2rx7−/− enterocytes as well as at the basolateral 
side of these cells. We cannot rule out that the contribution of GLUT2 to the overall increase in blood glucose 
level might also come from the modulation of GLUT2 expression at the basal compartment of enterocytes thus 
favoring glucose exit toward the bloodstream. Nevertheless, the overall effect resulting from the absence of a 
functional P2X7 in enterocytes was an increase in enteral absorption of glucose and a significant augmentation 
in the level of circulating glucose. In fact, we have shown that [18F]-FDG rapidly accumulates in the highly vascu-
larized muscle shoulder and blood of P2rx7−/− mice when compared to P2rx7+/+ animals. Hence, the glycaemia 
in male P2rx7−/− mouse was increased in OGTT assays when compared to control P2rx7+/+ littermates. The 
apparent discrepancy between the levels of circulating glucose and the [18F]-FDG activity measured in the heart 
of P2rx7−/− mouse could be explained by the diabetic phenotype and the presence of hepatic steatosis in P2rx7−/− 
mice. Indeed, it was showed that there is a drastic shift toward the utilization of fatty acids as the sole source of 
energy in the diabetic heart26. Hence, it was observed that diabetic patients with liver steatosis have decreased 
myocardial glucose uptake38.
The increase glycaemia that we measured in P2rx7−/− mice under basal fasting condition and following oral 
glucose challenges might also come from the reduced capacity of peripheral organs to adequately absorb glu-
cose as we showed using IPGTT. We observed that the blood glucose concentration was higher 15 and 30 min 
following the glucose injection as compared to control animals. Similar results were obtained in P2rx7−/− mice 
fed a high-fat/high-glucose diet13. Glucose absorption by peripheral organ is mainly regulated by the presence 
of insulin and organs capacity to respond to circulating insulin. In this study, along with elevated glycaemia val-
ues, we measured elevated insulin concentrations in P2rx7−/− animals; thus suggesting that knockout animals 
could produce insulin but that this production was not sufficient to regulate glycaemia. The higher glycaemia 
measured in P2X7−/− mice despite elevated serum insulin concentrations could be a sign of insulin resistance. 
Higher HOMA2-IR values in P2rx7−/− mice and significant higher glycemic values in intraperitoneal insulin 
tolerance tests in KO animals are supportive of this idea. Although euglycemic clamp tests could have better 
confirmed this finding, HOMA2-IR and HOMA2-%B values integrate normalized factors that give an accurate 
estimation of insulin resistance (IR) and β-cell functions (%B)39–41. In a previously published study, it was shown 
that the absence of P2X7 receptor expression reduced the overall pancreatic secretion in cell preparation iso-
lated from mice42, and that P2rx7−/− mice had impaired β cells function13. However, in this study, the calculated 
HOMA2-%B values were similar between P2rx7+/+ and P2rx7−/− mice, thus suggesting that pancreatic β-cell 
malfunction was not involved in terms of regulating the response to glucose challenges. In fact, the HOMA values 
that we obtained in our study are comparable to data that were measured in the fat-induced diet in the ob/ob mice 
model of insulin resistance36. These results are supporting the idea that the loss of P2X7 expression and function 
might also contribute to insulin resistance along with the increase efficiency of enterocytes to absorb and trans-
port glucose.
In the liver, activation of the P2X7 receptor was associated to tissue injury by promoting fibrosis43, inflam-
mation and oxidative stress44. Hence, peritumoral P2X7 expression in hepatocellular carcinoma was linked to 
an unfavorable prognostic for patient survival45. In our study, along with the apparent insulin resistance, high 
blood glucose levels and dyslipidemia, we observed an important accumulation of lipid droplets in hepatocytes of 
P2rx7−/− mice that is often associated with hepatic steatosis46. Hepatic steatosis is generally accompanied by the 
increase expression of Acaca, Acacb, Fasn and Acox1 in the liver to compensate for the presence of free fatty acid29. 
Surprisingly, we measured a reduction in the expression of these genes in the liver of KO animals, as well as in 
the expression of ACC and FAS at the protein level. However, the reduction of Acaca and Acacb expression in the 
liver of P2rx7−/− mice could explain the presence of hepatic fat since the abrogation of Acaca and Acacb expres-
sion in double knockout mice leads to an accumulation of hepatic fat47. The reduction in Acox1 expression that 
we measured in our animal model was also observed in the Acaca and Acacb double knockout mouse model47. 
Similarly, the loss of Acox1 expression was reported in a mouse model of high-fat diet-induced hepatic steatosis48. 
It was argued that the decrease β-oxidation resulting from the reduction of Acox1 expression could drive the lipid 
processing pathway towards lipid synthesis and away from catabolism, thus to accumulation of hepatic lipids48. 
Moreover, the disruption of Acox1 expression leads to the development of lipid microvesicules in steatosis liver49, 
similar to some of the observations we made in our study. Furthermore, it was reported that ACACA and FAS 
protein expression was significantly reduced in the liver of obese patients diagnosed with severe steatosis28. Given 
that signs of hepatic steatosis are already visible in 21-day-old mice, we could argue that our 3-month mice are 
suffering from advance liver steatosis as shown in Fig. 6G. This finding correlates well with the increased blood 
glucose levels; increased body weight, dyslipidemia and apparent insulin resistance found in the 3-month-old 
P2rx7−/− mice, as all of these parameters could be associated with liver steatosis47.
As an endocrine organ, the intestine secretes numerous gastrointestinal hormones regulating the metabolism50,51. 
This unique organ is also the center of nutrient absorption, including glucose. In this context, we previously 
reported that activation of the P2X7 by ATP lead to a reduction of glucose absorption and transport by IEC 
in vitro4. In this study using P2rx7−/− mice, we validated these previous observations and established that 
P2X7 was an important factor to modulate intestinal glucose absorption and transport using live PET imaging. 
Furthermore, we have provided strong evidence that P2X7 might contribute to the establishment of a metabolic 
dysregulation, mainly with regards to glucose and lipids homeostasis. These are metabolic conditions that are 
increasingly prevalent worldwide. Hence, our results suggest that regulation of P2X7 activity through the use 
of antagonists as potential therapies for inflammatory diseases and cancer52 might be cautiously examined for 
potential metabolic adverse effect. Nonetheless, the use of P2X7 ligands to control enteral glucose transport offers 
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an interesting perspective in the management of glycaemia. However, to develop this type of intervention we 
will have to develop strategies to target the P2X7 receptor expressed by IECs as previously reported4. As such, 
the systemic administration of P2X7 ligands might not be the solution as it could lead to immunoregulatory 
responses. In this context, orally available Pfizer CE-224,535 and GSK1482160 P2X7 receptor antagonists are 
potential candidates53,54. However, the action of both molecules was reported in the blood stream of patients, thus 
having systemic effect. Hence, the enteric distribution and activity of both compounds remain to be determined. 
Nevertheless, these studies clearly illustrate that targeting the P2X7 receptor in pathologies is far from being a 
fantasy. Furthermore, for this study we have developed an innovative modality of using [18F]-FDG and live PET 
imaging to follow enteral glucose transport. This particular modality in the use [18F]-FDG could lead to innova-
tive approaches to study glucose metabolism and biodistribution in live organism such as human.
Methods
Animals. Adult B6.129P2-P2rx7tm16ab/J and C57BL/6J mice were purchased from Jackson Laboratory (Bar 
Harbor, ME). B6.129P2-P2rx7tm16ab/J mice were backcrossed with C57BL/6J mice for 10 generations. Experiments 
were performed with F10 and following generations. Mice genotype was determined using the previously 
described NaOH-based genomic DNA extraction protocol55. The genotype was determined by PCR amplifi-
cation using the following oligonucleotide primers: 5′-TCACCACCTCCAAGCTCTTC-3′ for wild-type ani-
mals (P2rx7+/+), 5′-GCCAGAGGCCACTTGTGTAG-3′ for P2rx7−/− mouse and a common reverse primer 
5′-TATACTGCCCCTCGGTCTTG-3′. Mice were housed as previously described56. As indicated, prior to some 
experiments, mice were starved for 6 h during the daytime to circumvent the metabolic and catabolic stress 
induced by longer nocturnal starvation period as reported57,58.
Monitoring mouse food uptake, locomotion and energy expenditure. The Promethion 
High-Definition Room Calorimetry System was used for the indirect calorimetry studies (GA3, Sable Systems, 
Las Vegas, NV). Prior to acquisition eight-12-week-old male mice (4 P2rx7+/+ and 4 P2rx7−/−) were acclimated 
to cages for 48 h. A standard 14 h light- 10 h dark cycle was maintained and animals had access ad libitium to 
standard chow and water. For the experiments, mice had ad libitium access to standard chow and water. Data 
acquisition and instrument control were coordinated by MetaScreen v. 1.6.2 and the obtained raw data was pro-
cessed using Expe-Data v. 1.4.3 (Sable Systems, Las Vegas, NV) using an analysis script detailing all aspects of 
data transformation. For this study, we focused on food uptake, animal locomotion and energy expenditure (EE). 
Results for food uptake (gram), locomotion (meter) and EE (kcal/hr) were presented as the mean ± SEM in func-
tion of the circadian cycle.
Tissues processing. Excised jejunums were flushed of debris using PBS as previously described56, and either 
used for epithelial cell enrichment for RNA and protein expression analysis or fixed in Carnoy solution (60% 
methanol, 30% chloroform, 10% glacial acetic acid) and used for paraffin embedding for immunohistochemical 
analyses. Liver sections were also isolated and used for RNA and protein expression analysis or fixed in 3% PFA 
and embedded in paraffin for subsequent histologic studies. Alternatively, liver sections were placed in a 30% 
saccharose cryoprotective solution as described by Drover59 prior to OCT inclusion and Oil Red O staining by 
the Electron Microscopy and Histology Research Core from the Université de Sherbrooke Faculty of Medicine 
and Health Sciences. For the Oil Red O staining quantification, image acquisition from stained liver sections was 
performed using a Hamamatsu Nanozoomer apparatus under bright field illumination. The zoom was set at 20x 
and the presence of red pixels measured using Adobe Photoshop and a predefine array of different red shades 
enriched for magenta color. An average of at least 3 different fields per mice were measured for the quantification 
analysis.
GLUT2 immunohistochemistry. Male P2rx7+/+ and P2rx7−/− mice were starved for 6 h prior to exper-
iments. Jejunum sections (5 μm) were deparaffinized, rehydrated and treated with Dako peroxidase blocking 
solution (Agilent Technologies Canada, Inc., Mississauga, ON). Jejunum slides were treated with the avidin/bio-
tin blocking kit (Vector laboratories, Brockville, ON) and non-immunogenic sites blocked with PBS containing 
0.1% Tween 20 and 2% BSA (PBT-BSA). Slides were incubated with goat polyclonal anti-GLUT2 (C-19) (Santa 
Cruz Biotech, Santa-Cruz, CA) antibodies at a dilution of 1:100 in PBS-BSA for 2 h at room temperature (RT). 
Slides were washed in PBS and incubated with biotinylated rabbit anti-goat IgG (1:200; Vector laboratories) in 
PBT-BSA for 1 h at RT followed by incubation with the Vectastain biotinylated horseradish Peroxydase H Elite 
ABC Kit (Vector laboratories) and revealed with the Dako DAB and chromogen solution (Agilent Technologies 
Canada, Inc.). Slides were counterstained with a hematoxylin solution following the manufacturer instructions 
(Sigma-Aldrich, Oakville, ON) and mounted using VectaMount mounting medium (Vector laboratories). Slides 
were scanned at 40 X with Hamamatsu Nanozoomer 2.0-RS system and analysed with the NDP scan software.
Live glucose absorption by Positron Emission Tomography (PET) and [18F]-FDG biodistribution 
assays. PET imaging and 18F-FDG biodistribution were assessed on three-month-old male mice starved for 
6 h prior to the experiment as described above. Mice were gavaged with 100 μl of a 500 mg/mL glucose solution 
containing 3 to 5 MBq of 18F-FDG using a 24G × 1” W/1.25 mm gavage needle (Cadence Inc., Staunton, VA). 
Animals received the radioactive glucose solution in less than 15 seconds, rapidly anesthetized in 2–4 minutes 
by isoflurane inhalation in a pre-saturated chamber and placed in a LabPET/Triumph PET/CT scanner (Gamma 
Medica, Northridge, CA) for a 90 min live acquisition of 18F-FDG distributions. Dynamic PET acquisition data 
were reconstructed as a series of 26 images frames (10 × 1 minute, 16 × 5 minutes) and radioactivity uptake in 
selected organs was extracted by region-of-interest analysis. Measured radioactivity data, corrected for 18F decay 
(half-life of 110 min) referred to time of injection, were converted as the % of injected dose/g of tissue (%ID/g) 
given that 1 g of tissue is estimated at 1000 μl following virtual tissue reconstruction. PET image visualization, 
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analysis and 3D rendering were performed using the AMIDE software60. Following the 90 min acquisition, organs 
of interest, as presented in Fig. 2, were harvested to measure the 18F-FDG biodistribution. Briefly, whole tissues 
were placed in 12 × 75 mm tubes and 18F-FDG emissions measured using a Packard Cobra II E5003 gamma 
counter (Perkin Elmer, Waltham, MA). The %ID/g values were corrected based on the initial injected dose cor-
rected for the 18F-FDG-decay factor.
Western immunoblotting. Intestinal epithelial cells were isolated from the isolated jejunums using the 
BD Cell recovery solution as previously described56, and homogenized in Triton buffer (40 mM Tris pH 7.5, 
150 mM NaCl, 1 mM EDTA, 1% Triton X-100, 0.2 mM sodium orthovanadate, 50 mM sodium fluoride, 40 mM 
β-glycerophosphate, 0.1 mM phenylmethylsulfonyl fluoride and protease inhibitor mixture from Sigma-Aldrich). 
Livers were also harvested and homogenized as described above. Protein samples were processed as described61, 
with the omission of the heat-denaturation step. Proteins were separated on a 7% SDS-PAGE and transferred to 
polyvinylidene fluoride membranes for protein immunoblotting. Immunoblotting for protein expression was 
performed using a 1:750 dilution of rabbit polyclonal anti-P2X7 (APR-004) antibody (Alomone Labs, Jerusalem, 
Israel), 1:1000 dilution of rabbit polyclonal anti-GLUT2 (H67) antibody, 1:1000 dilution of goat anti-PPARα and 
anti-PPARβ antibodies (Santa Cruz Biotech, Santa Cruz, CA), 1:1000 dilution of rabbit polyclonal anti-AMPK 
and rabbit monoclonal anti-phospho AMPK (Thr172) (New England Biolabs, Ltd., Whitby, ON, Canada), 1:2000 
dilution of rabbit polyclonal anti-ACC and of rabbit monoclonal anti-FAS antibodies (New England Biolabs, Ltd., 
Whitby, ON, Canada). The antibodies were diluted in PBS containing 5% BSA or in PBS containing 0.1% Tween-
20 and 0.5% fish gelatin and incubated overnight at 4 °C. Specific protein bands were detected using a 1:10000 
dilution of horseradish peroxidase (HRP)-conjugated anti-rabbit IgG (GE Healthcare Life Sciences, Mississauga, 
ON) or 1:5000 HRP-conjugated donkey anti-goat IgG (Santa Cruz Biotech, Santa Cruz, CA) and visualized on 
autoradiographic film using the Millipore chemiluminescence system. Signal normalization was performed as 
described previously using a 1:1000 dilution of mouse monoclonal anti-Vinculin or anti-GAPDH (Millipore, 
Etobicoke, ON), or 1:5000 dilution of rabbit monoclonal anti-β-Tubulin antibody (New England Biolabs, Ltd., 
Whitby, ON, Canada) and 1:10000 dilution of HRP-conjugated anti-mouse or anti-rabbit IgG (GE Healthcare 
Life Sciences). Crude lung homogenates, isolated from P2rx7+/+ animals, was used as a positive control for P2X7 
expression.
Serum glucose, triglycerides (TG), cholesterol and insulin quantification. Blood was collected by 
cardiac puncture of the right ventricle of 6 h-fasted mice. After 30 min at room temperature, samples were cen-
trifuged at 3,000 × g for 15 min at 4 °C. Serum insulin levels were quantified by ELISA using the rat/mouse insu-
lin Millipore ELISA kit (EZRMI-13K). Serum glucose, cholesterol and TG concentrations were measured using 
commercially available kits (Siemens Healthcare Diagnostics, Deerfield, IL) on a clinical analyzer (Dimension 
XPand Plus, Dade Behring Inc.) as described27,62. Relative insulin resistance and pancreatic β-cell function were 
estimated using the Homeostasis Model Assessment 2-Insulin Resistance test (HOMA2-IR) and HOMA2-%B 
(http://www.dtu.ox.ac.uk/homacalculator/index.php).
Glucose and insulin tolerance tests. Oral glucose tolerance tests (OGTT), intraperitoneal glucose toler-
ance tests (IPGTT) and intraperitoneal insulin tolerance tests (IPITT) were realized on 3-month-old male mice 
starved for 6 h as described above. For OGTT, mice were gavaged with 100μl of a 500 mg/ml D-glucose solution 
using a 24 × 1” W/1.25 mm gavage needle (Cadence Inc.). For IPGTT and IPITT, 2 g D-glucose/kg or 0.5 U/kg 
of insulin (Novolin®ge Toronto, Novo Nordisk Canada, Inc., Mississauga, ON) were respectively injected intra-
peritoneally. Blood glucose values were determined from whole venous blood obtained from mice tails using a 
glucose monitor (FreeStyle Lite; Abbott Diabetes Care). Results were plotted as the variation of glycaemia over 
time using GraphPad Prism and the area under the curve (AUC) calculated by the trapezoidal methods to estab-
lish the overall amount of blood present in the circulation after 90 min.
Quantitative real-time PCR analysis. Total RNA was isolated from the liver of 12-week-old mice using 
the ToTALLY RNA Total RNA Isolation Kit (Thermo Fisher Scientific) and RNA purified Qiagen RNeasy minikit 
(Qiagen, Toronto, ON). Complementary DNA was synthesized from 2 μg of purified RNA as previously described63. 
Quantitative real-time PCR analyses were realized as previously reported63 using the mouse sequence-specific 
primers for Acaca: 5′-GATGAACCATCTCCGTTGCG-3′ and 5′-GAGCCAATTATGAATCG GGACTG-3′, 
Acacb: 5′-TTCCCCAGCCAGCAGATAGC-3′ and 5′-CTTCATGTAGCCACGGGTCC-3′, Fasn: 5′-GAT 
GAAGAGGGACCATAAAGAATAA-3′ and 5′-GCACTTGATGTGAG GGGAGAT3′, Acox1: 5′-CCGCCA 
CCTTCAATCCAGAG-3′ and 5′-CAAGTTCTCGATTTCTCGACGG-3′, and Mlxipl: 5′-CTGGGGAC 
CTAAACAGGAGC-3′ and 55′-GAAGCCACCCTATAGCTCCC-3′. Gene expression was normalized to Tbp 
gene expression as previously reported64.
Statistics. Results are expressed as the mean ± standard error of the mean (SEM). Statistical significance was 
determined by a multiple comparison unpaired t test for data having a normal Gaussian distribution or corrected 
for Mann-Whitney for non-normal distributed results. The number of replicates and animals for each experiment 
are presented in figure legends.
Study approval. All procedures were performed according to the protocol #217-13BR that was approved 
by the Université de Sherbrooke Animal Care Committee and the Canadian Guidelines for Care and Use of 
Experimental Animals.
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Availability of data and material. All data generated or analyzed during this study are included in this 
article and its supplementary information files.
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